Trastuzumab Deruxtecan: Effects in Multiple Cancer Types Trastuzumab Deruxtecan: Effects in Multiple Cancer Types
Dr Maurie Markman discusses the concept of focusing on a particular molecular target and then potentially looking at the value of that drug across multiple tumor types.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. CELU ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present in vivo data from its T-cell therapy platform at this year's…#celularityinccelu #aacrannualmeeting #celularity #ptcd16vs #roberthariri #adriankilcoyne #sandiego #section21e #tcr #trastuzumab (Source: Reuters: Health)
Source: Reuters: Health - March 7, 2024 Category: Consumer Health News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news

The UCLA Research Park: Immunology and immunotherapy
With the California Institute for Immunology and Immunotherapy at UCLA as an anchor tenant at theUCLA Research Park on the site of the former Westside Pavilion shopping mall, UCLA is poised to enter a new era of biomedical breakthroughs.A first-of-its kind effort in California, the nonprofit public-private partnership will leverage UCLA ’s existing strengths in clinical and biomedical scientific research across a range of disciplines. Top-flight scientists from UCLA and around the world will pursue new tools, treatments and vaccines to address a variety of pressing health challenges, including cancer, infectious diseases...
Source: UCLA Newsroom: Health Sciences - January 3, 2024 Category: Universities & Medical Training Source Type: news

Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer
Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news

Wendy Harris is spearheading the Wisconsin Biohealth Tech Hub
After she was diagnosed with breast cancer nearly two decades ago at the age of 39, a form of personalized medicine offered a treatment for Wendy Harris. Fighting an aggressive tumor, she participated in a clinical trial for Herceptin — a new treatment at the time that was suited for her type of cancer. "It saved my life," Harris said. "It's now a standard of care, but at the time, that was brand new — kind of the first foray into personalized medicine and attacking each cancer uniquely for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 8, 2023 Category: Pharmaceuticals Authors: Teddy Nykiel Source Type: news

HER2+ Combo Shows Promise in Breast Cancer Brain Mets HER2+ Combo Shows Promise in Breast Cancer Brain Mets
In previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Adding tucatinib (Tukysa) to trastuzumab emtansine (T-DM1; Kadcyla) reduced the risk of disease progression or death by 24% in previously treated HER2-positive breast cancer patients with locally advanced unresectable... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 7, 2023 Category: Hematology Source Type: news